Franklin Resources’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$53.6M Buy
936,044
+2,165
+0.2% +$119K 0.01% 651
2026
Q1
$52.8M Buy
933,879
+838,778
+882% +$48.9M 0.01% 634
2025
Q4
$5.65M Sell
95,101
-11,838
-11% -$644K ﹤0.01% 1351
2025
Q3
$5.79M Sell
106,939
-303,853
-74% -$17.4M ﹤0.01% 1369
2025
Q2
$22.6M Buy
410,792
+46,718
+13% +$2.75M 0.01% 889
2025
Q1
$25.7M Sell
364,074
-85,687
-19% -$5.76M 0.01% 827
2024
Q4
$29.6M Sell
449,761
-35,614
-7% -$2.39M 0.01% 791
2024
Q3
$34.1M Buy
485,375
+91,463
+23% +$7.65M 0.01% 718
2024
Q2
$32.4M Buy
393,912
+75,864
+24% +$6.32M 0.01% 696
2024
Q1
$27.8M Buy
318,048
+16,284
+5% +$1.46M 0.01% 762
2023
Q4
$29.1M Sell
301,764
-264,478
-47% -$23.4M 0.01% 659
2023
Q3
$50.1M Sell
566,242
-269,989
-32% -$24M 0.03% 491
2023
Q2
$72.5M Buy
836,231
+150,936
+22% +$14.2M 0.03% 431
2023
Q1
$66.6M Buy
685,295
+353,163
+106% +$36.6M 0.03% 457
2022
Q4
$34.4M Sell
332,132
-113,594
-25% -$10.7M 0.02% 630
2022
Q3
$37.8M Buy
445,726
+2,536
+0.6% +$226K 0.02% 608
2022
Q2
$36.7M Buy
443,190
+1,286
+0.3% +$102K 0.02% 634
2022
Q1
$34.1M Sell
441,904
-85,347
-16% -$7.14M 0.01% 710
2021
Q4
$46.6M Buy
527,251
+43,525
+9% +$3.59M 0.02% 656
2021
Q3
$37.4M Buy
483,726
+11,839
+3% +$934K 0.01% 739
2021
Q2
$39.4M Buy
471,887
+41,661
+10% +$3.3M 0.02% 712
2021
Q1
$32.5M Sell
430,226
-714
-0.2% -$58.3K 0.01% 734
2020
Q4
$37.8M Buy
430,940
+25,451
+6% +$2.02M 0.02% 667
2020
Q3
$30.8M Buy
405,489
+5,003
+1% +$506K 0.01% 668
2020
Q2
$51.1M Sell
400,486
-1,791
-0.4% -$178K 0.03% 523
2020
Q1
$34M Sell
402,277
-177,824
-31% -$15.3M 0.02% 554
2019
Q4
$49M Sell
580,101
-652,766
-53% -$49.3M 0.03% 547
2019
Q3
$83.1M Sell
1,232,867
-217,234
-15% -$16.7M 0.05% 409
2019
Q2
$124M Sell
1,450,101
-2,567
-0.2% -$220K 0.07% 310
2019
Q1
$129M Buy
1,452,668
+180,239
+14% +$16.7M 0.07% 302
2018
Q4
$108M Sell
1,272,429
-31,577
-2% -$3M 0.07% 313
2018
Q3
$126M Sell
1,304,006
-390,061
-23% -$38.9M 0.06% 321
2018
Q2
$160M Buy
1,694,067
+323,051
+24% +$28.3M 0.08% 261
2018
Q1
$111M Sell
1,371,016
-339,556
-20% -$29.1M 0.06% 337
2017
Q4
$153M Buy
1,710,572
+80,568
+5% +$7.01M 0.07% 277
2017
Q3
$152M Sell
1,630,004
-81,017
-5% -$7.16M 0.07% 277
2017
Q2
$155M Buy
1,711,021
+88,964
+5% +$8.09M 0.08% 263
2017
Q1
$142M Buy
1,622,057
+480
+0% +$42.7K 0.07% 279
2016
Q4
$134M Sell
1,621,577
-25,319
-2% -$2.18M 0.07% 276
2016
Q3
$152M Buy
1,646,896
+284,900
+21% +$26.8M 0.08% 259
2016
Q2
$106M Buy
1,361,996
+1,106
+0.1% +$94K 0.06% 335
2016
Q1
$112M Sell
1,360,890
-122,249
-8% -$9.95M 0.06% 319
2015
Q4
$155M Buy
1,483,139
+73,450
+5% +$7.67M 0.08% 259
2015
Q3
$148M Sell
1,409,689
-298,544
-17% -$39.9M 0.07% 274
2015
Q2
$234M Buy
1,708,233
+185,068
+12% +$22.9M 0.11% 214
2015
Q1
$190M Sell
1,523,165
-60,600
-4% -$6.42M 0.09% 249
2014
Q4
$143M Sell
1,583,765
-65,900
-4% -$5.48M 0.06% 289
2014
Q3
$119M Sell
1,649,665
-175,500
-10% -$11.5M 0.05% 323
2014
Q2
$114M Buy
1,825,165
+111,000
+6% +$6.71M 0.05% 353
2014
Q1
$117M Buy
1,714,165
+375,900
+28% +$27.7M 0.06% 337
2013
Q4
$94M Sell
1,338,265
-148,000
-10% -$10.1M 0.05% 381
2013
Q3
$107M Buy
1,486,265
+528,100
+55% +$35.1M 0.06% 334
2013
Q2
$53.5M Buy
+958,165
New +$59.7M 0.03% 493

Other funds holding BMRN

Franklin Resources's BMRN Position: Q2 2026 in Review

Franklin Resources increased its BioMarin Pharmaceuticals (BMRN) stake by 0.23% in Q2 2026, buying an estimated $119K and bringing the position to 936,044 shares worth $53.6M. The position accounts for 0.01% of the portfolio, ranked #651.

Franklin Resources first reported a position in BMRN in Q2 2013 and has held it in 53 quarters since. The position peaked at $234M in Q2 2015. 561 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Franklin Resources held 936,044 shares of BioMarin Pharmaceuticals worth $53.6M as of Q2 2026.
  • Franklin Resources bought 2,165 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $119K.
  • BioMarin Pharmaceuticals made up 0.01% of Franklin Resources's portfolio in Q2 2026, its #651 holding.
  • Franklin Resources first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Franklin Resources's BioMarin Pharmaceuticals position peaked at $234M in Q2 2015.
  • 561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Franklin Resources's 13F filing for Q2 2026, filed 13 Aug 2026.